was: Composite fair value: $48.40 → signal-adjusted: $49.98 vs current price $51.53 (-3.0%). Methods disagree — mixed signals. Treat the composite with caution. RED FLAG: Sector in contraction — demand weakening across the industry.

now: Planet Fitness at $51.53 is not priced for perfection, but it requires moderate-to-high conviction that the current trajectory continues without material disruption. The 19.7x P/E and 18% implied FCF growth are reasonable for a capital-light franchise business that has demonstrated execution excellence, but the thesis has three critical vulnerabilities that aren't adequately reflected in the price. First, the GLP-1 wildcard represents an asymmetric risk. If these drugs prove substitutional to gym usage rather than complementary, 15-25% of Planet Fitness's addressable market could permanently disappear within 5-7 years as adoption scales. The company has no obvious defense beyond hoping behavioral data proves favorable. The market is currently in 'wait and see' mode rather than preemptively discounting this risk, which creates downside optionality that isn't priced in. Second, the negative equity position is a hidden fragility. While the company isn't overleveraged in absolute terms, returning more cash to shareholders than cumulatively earned means any sustained earnings decline quickly becomes an existential threat. There's no balance sheet cushion to weather a storm or pivot strategy. This works brilliantly in a steady-state growth environment but creates cliff risk if the model breaks. Third, the margin expansion story is running out of runway. Going from 12.9% to 16.5% margins in three years is impressive, but getting to the 18-20% implied by the valuation without pricing power requires operating leverage that may not materialize if unit growth disappoints. The bull case is straightforward: Planet Fitness is the Walmart of gyms with a defensible moat in the value segment, 50%+ white space remaining in North America, and a franchise model that mints cash with minimal capital needs. If GLP-1 fears prove overblown and the economy cooperates, this compounds at mid-teens rates for years. The bear case is equally clear: GLP-1 adoption accelerates, demand shrinks, franchisee economics deteriorate, unit growth stalls, and the negative equity position forces aggressive deleveraging that craters the stock. At $51.53, you're betting the bull case is 60-70% likely. That's not unreasonable, but it's not a layup either. This is a 'own it if you have conviction, but size it appropriately' situation, not a core portfolio holding for investors who can't tolerate 30-40% drawdowns if the GLP-1 thesis breaks badly.

was: Undervalued — at 7x EBITDA with 27% earnings growth and accelerating Q1'26 revenue, fair value is $65-70, not $50; the synthesis model is mistaking a depressed multiple for fair value. Starter position warranted; add on any franchisee SSS confirmation.

now: —

was: I agree with Opus — undervalued at $51.53, with a fair value closer to $65-70; the growth trajectory and relative undervaluation to peers justify a higher target, albeit with caution regarding long-term macro risks.

now: I diverge from Opus — while the current trading multiple is not exorbitant, I see the fair value closer to $55, given the risks of market saturation and potential margin reversion, against Opus's $60-68 range.

was: The market has repriced PLNT from $114 to $51 (-55%) despite revenue growth and margin expansion, suggesting deep concerns about either: (1) GLP-1 weight loss drugs permanently reducing gym demand, (2) consumer recession risk to low-income cohort, or (3) franchisee stress that could impair the royalty stream. The current price implies significant growth deceleration or margin compression ahead.

now: The 55% drawdown from $114 to $51 suggests the market has abandoned the '3,000+ US stores' growth narrative and is now pricing PLNT as a mature franchise platform with single-digit unit growth. The current price likely embeds: (1) franchisee expansion plateau near current ~2,400 units, (2) same-store sales growth of 2-4% (population growth + modest pricing), and (3) equipment revenue normalization post-COVID reopening surge. At $51, market may be pricing 8-12% FCF yields with low growth, vs the 3-5% yields at $114 that assumed aggressive expansion.

was: GLP-1 drug adoption (Ozempic/Wegovy) could structurally reduce demand for budget gym memberships if weight loss becomes pharmaceutical rather than exercise-driven · Franchisee financial stress hidden in aggregate numbers - if franchisees struggle with rent, labor costs, or membership churn, royalty stream is at risk · Low-income consumer exposure - $10/month model targets price-sensitive cohort vulnerable to recession or inflation in necessities · Dramatic GM jump to 82.6% in 2025 could be accounting artifact rather than real margin improvement - needs verification before modeling · Refranchising creates one-time gains but may signal company stores are underperforming - watch for asset quality issues

now: Franchisee economics deterioration: If new store ROIs compress due to saturation, real estate costs, or wage inflation, unit growth halts and equipment segment collapses. Check franchisee-level unit economics if disclosed. · GLP-1 drug adoption (Ozempic, Wegovy): If weight-loss drugs reduce gym membership demand, PLNT's budget positioning makes it most vulnerable—customers can't justify $15/month if not using it. Premium gyms (LTH) have stickier social/amenity value. · Debt maturity wall risk: Balance sheet shows zero cash and zero disclosed debt, but successful franchise platforms often carry significant leverage from buybacks/recaps. Hidden debt maturity risk could exist. · Corporate store divestiture accounting: The 82.6% GM jump smells like segment mix shift or accounting change. If they're selling corporate stores to franchisees at gains, reported earnings may be overstated vs sustainable run-rate. · Equipment segment cyclicality: 25% of revenue from lumpy equipment sales to new franchisees. If store openings drop 30%, equipment revenue could drop 50%+ with high operating leverage.

was: International expansion success in Canada, Australia, Mexico could provide new growth vector and validate brand portability · Same-store sales acceleration would confirm brand resilience against GLP-1 concerns and consumer pressure · Membership pricing power - any ability to raise from $10/month without churn would dramatically boost franchisee and company economics · Equipment segment margin expansion if 2025 GM spike is sustainable - could indicate pricing power with franchisees · Debt refinancing or capital allocation shift - franchise platforms often lever up to return capital when growth moderates

now: Franchisee unit growth re-acceleration: Any evidence of new franchisee commitments or white-space expansion (international, underserved US markets) would signal growth narrative isn't dead. · Same-store sales inflection: If existing gyms show 5-7%+ membership growth (vs 2-3% baseline), suggests brand strength and pricing power remain intact despite GLP-1 concerns. · Corporate store divestiture completion: If they exit all corporate stores, steady-state margins could stabilize at 80%+ with pure franchise/equipment model. Removes operational distraction. · Strategic acquisition: Rolling up regional gym chains and converting to PLNT brand could reignite unit growth without franchisee capital constraints. · Capital return acceleration: With strong FCF generation and apparent negative equity, aggressive buyback program could create technical support and signal management confidence in valuation floor.

was: —

now: Array